MRIAIEEGEpidemiology

Psychiatric biomarkers

Severe psychiatric disorders, transdiagnostic approaches, objective biomarkers, and neuromodulation treatments.

Leader

Pr. Ali Amad

members

5

Objectives

This group explores severe psychiatric disorders through three axes: (1) the clinical redefinition of psychiatric disorders, particularly mood disorders, by identifying objective clinical biomarkers (extracted via AI and computer vision); (2) the transdiagnostic and neurobiological study of catatonia; (3) the analysis of the efficacy, mechanisms, and accessibility of physical treatments in psychiatry (ECT and neuromodulation treatments).

Population

  • Patients suffering from mood disorders
  • Patients presenting with psychotic disorders or symptoms
  • Patients affected by catatonia, across all etiologies
  • Psychiatric populations exposed to physical and neuromodulation treatments
  • National medico-administrative databases (SNDS, PMSI)

Methods

  • Computer vision and extraction of clinical biomarkers
  • Artificial Intelligence (supervised and unsupervised machine learning, NLP, multimodal predictive models)
  • Brain imaging (structural and functional MRI), genetics, and biological analysis
  • Epidemiology
  • Digital tools for clinical assessment

Team members

Leader

Pr. Ali Amad

Pr. Ali Amad

Professor of Psychiatry

ali.amad@chu-lille.frFull Professor

Team

  • Dr. Clémence Nineuil

    Dr. Clémence Nineuil

    Psychologist

  • TM

    Tomas Mastellari

    PhD Student, Psychiatrist

  • LC

    Lucie Cherruaud

    PhD Student, Psychiatrist

  • Fouad Boutaleb

    Fouad Boutaleb

    PhD Student, Engineer

Publications

2026
5 publications

Functional Somatic Disorder: a Post-Medical event Stress Disorder?

Horn M, Fovet T, Lemogne C, Vaiva G, Amad A, D'Hondt F · Journal of the Academy of Consultation-Liaison Psychiatry

Consultation-liaison Psychiatry Interventions: The Sooner, the Better.

Demesmeaker A, Fovet T, Amad A, D'Hondt F, Horn M · Biopsychosocial science and medicine

Deterioration of Psychiatric Care in French Prisons.

Fovet T, Amad A · The International journal of social psychiatry

Multi-level language deficits in behavioural frontotemporal degeneration and related disorders.

Denève A, Mahut Dubos A, Tran TM, Renard A, Carpentier C, Forestier N, Kuchcinski G, Lopes R, Amad A, Lebouvier T, Bertoux M · Brain communications

[The hearing with the "custody and liberty judge": How is it perceived by incarcerated people involuntary hospitalized?].

Watteau M, Eck M, Horn M, Amad A, Wathelet M, Fovet T · L'Encephale

2025
3 publications

Correction: Psychiatric adverse events associated with infliximab: a cohort study from the French nationwide discharge abstract database.

Thillard EM, Gautier S, Babykina E, Carton L, Amad A, Bouzillé G, Beuscart JB, Chazard E · Frontiers in pharmacology

Predicting the response to Lorazepam in catatonia: a network analysis approach.

Mastellari T, Gauld C, Fovet T, Amad A · Progress in neuro-psychopharmacology & biological psychiatry

Bright Light Therapy in the Morning or Midday for the Treatment of Nonseasonal Depression in Bipolar Disorder (LuBi): A Dose-Escalation Phase 1/2 Randomized Double-Blind Trial.

Geoffroy PA, Chevret S, Mauries S, Chaffaut C, Amad A, Bellivier F, Benard V, Courtet P, Dubertret C, Gorwood P, Mazer N, Mekaoui L, Olié E, Pataud G, Vaiva G, Lejoyeux M, Sit D, Maruani J · The Journal of clinical psychiatry

Next groupSocial neuropsychologyDr. Maxime Bertoux